Two Phase 3s target low-intensity follicular lymphoma standards: surovatamig vs radiotherapy, mosunetuzumab vs rituximab

An agent that the public chemistry registry ChEMBL still lists at maximum phase 2, with its mechanism and target fields empty, is registered to open a randomised Phase 3 against standard-of-care radiotherapy in follicular lymphoma on 12 January 2027 ^[3][2]. That is surovatamig, in NCT07736950 — a trial with a planned 138 patients run by the Australasian Leukaemia and Lymphoma Group in limited-stage nodal disease, with event-free survival as the primary outcome and a primary completion date of 13 January 2035 ^[2]. The trial is not yet open to enrolment ^[2].

It surfaced in the same 6 August 2026 sweep of ClinicalTrials.gov as a second Phase 3 aimed at the other lightly-treated end of the disease: the National Cancer Institute's NCT06337318, open since 23 October 2024 and currently recruiting toward a 600-patient enrolment target, randomising patients with low tumour burden follicular lymphoma between rituximab and mosunetuzumab, with a primary completion date of 31 March 2032 ^[1]. Two trials, and in each the low-intensity registered option sits on one side of the randomisation: rituximab in one — the established agent in this setting, which reads as the comparator, though the record reviewed does not label the arms as experimental and control ^[1] — and in the other a three-week radiotherapy course, or radiotherapy plus six weekly rituximab doses over six weeks ^[2].

What the two records actually say

NCT06337318 is sponsored by the National Cancer Institute and covers classic follicular lymphoma and follicular lymphoma with unusual cytological features ^[1]. Registered interventions are mosunetuzumab, rituximab, and a rituximab-and-hyaluronidase-human preparation, alongside biospecimen collection, computed tomography and positron emission tomography ^[1]. Two primary outcomes are registered: three-year milestone progression-free survival, and progression-free survival ^[1]. Whether the randomisation runs two arms or three, and whether that second progression-free survival outcome uses a different measurement window from the three-year milestone, are not established in the record reviewed.

The registry's own framing is unusually bare. Rituximab is described as a monoclonal antibody that binds CD20, found on B cells and some cancer cells; mosunetuzumab is described only as "a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread"; and the summary states it is not yet known which works better in low tumour burden disease ^[1].

NCT07736950 tests whether surovatamig works better than standard-of-care involved-site radiotherapy, with or without rituximab, in limited-stage disease, and also assesses the drug's safety ^[2]. Dosing runs four cycles: cycle 1 carries a three-step ramp-up over 14 days, and cycles 2 to 4 run 28 days each with drug given every fortnight ^[2]. The comparators are radiotherapy alone for three weeks, or radiotherapy plus rituximab weekly for six doses over six weeks ^[2]. Follow-up is a clinic visit each cycle, one at end of treatment, then every three months in year one, every six months in year two, and once a year in years three to five ^[2].

The comparator is the whole story

In advanced, high tumour burden disease the argument for a new agent writes itself: follicular lymphoma is the most common indolent lymphoma, chemoimmunotherapy is effective, and toxicity remains problematic enough that novel treatments are required — that is the stated rationale of the LEVERAGE Phase Ib/II study in treatment-naïve, high tumour burden, advanced-stage patients ^[6]. Neither of these two trials is fighting that fight.

They are fighting the opposite one. In each, the comparator is low-intensity active therapy rather than chemoimmunotherapy ^[1][2]. Cycles 2 to 4 of surovatamig alone span 84 days with dosing every fortnight, on top of a cycle 1 whose three-step ramp-up runs 14 days and whose total length the record reviewed does not state ^[2]. On Prognyx's arithmetic that puts the experimental arm at a minimum of 98 days of scheduled therapy, and 112 days if cycle 1 runs 28 days like the cycles that follow — the record does not say which ^[2]. Set against that: three weeks of radiotherapy alone, or six weeks where rituximab is added, with the radiotherapy delivery schedule itself not specified in the record ^[2] — a longer commitment on the calendar for the experimental arm, not necessarily a heavier visit burden. On the NCI side, the comparator is rituximab, registered both as rituximab and as a rituximab-and-hyaluronidase-human preparation, with no chemotherapy registered alongside it ^[1]; no route of administration for either form appears in the fields reviewed ^[1]. No dosing schedule for either agent appears in the fields reviewed, so no equivalent duration comparison can be made here ^[1]. The endpoint choices are consistent with a durability argument rather than a speed one: three-year milestone progression-free survival and event-free survival, with primary completion dates of 31 March 2032 and 13 January 2035 ^[1][2]. Note the distinction: a primary completion date is when the primary outcome data are due to be collected, not a readout and not a verdict.

What the public record does not establish

This is the section that governs everything above it, and it is unusually long for two Phase 3 records.

Safety. No adverse-event data, no cytokine release syndrome rate, no neurological toxicity rate and no boxed-warning text for either mosunetuzumab or surovatamig appears in the primary sources reviewed. NCT07736950 states that it assesses the drug's safety; it reports none, and no results are posted for either trial ^[1][2].

Mechanism. The class labels routinely attached to these agents are not in the records. ChEMBL carries no mechanism and no target for surovatamig ^[3]. The only characterisation available is a 16 June 2025 Pharmaceutical Technology headline, surfaced via a news aggregator, reading "EHA 2025: Surovatamig emerges as BiTE for R/R B-AL" — a headline with no accompanying article text in the sources reviewed, unconfirmed in the primary sources reviewed, and carrying a truncated indication string that should not be read as a specific disease ^[4]. The NCI record does not describe mosunetuzumab as a CD20xCD3 bispecific ^[1]. The class itself is well characterised in the literature — bispecific T cell engagers and higher-order multispecifics redirect immune effector cells toward tumour targets ^[7], and bi- and multispecific antibodies have advanced over two decades by binding two or more distinct antigens or epitopes ^[8] — but a class description is not a molecule's mechanism, and neither review names either agent here.

Ownership and regulatory status. A 23 April 2026 aggregator headline attributes surovatamig to AstraZeneca and reports an EU orphan drug designation in large B-cell lymphoma ^[5]. Prognyx holds this as secondary reporting only: no company release, no EMA or EU register entry and no securities filing corroborates it, and NCT07736950 names the Australasian Leukaemia and Lymphoma Group as sponsor without naming AstraZeneca in the fields reviewed ^[2][5]. An orphan designation, if granted, is an incentive status and carries no review clock; no marketing application, review designation or target action date for either agent appears in the sources reviewed, so no decision window can be derived here for either.

Eligibility and comparator choice. The definitions of "low tumour burden" in NCT06337318 and "limited stage" in NCT07736950 are not in the records reviewed, so the exact patients each trial will take remain unspecified ^[1][2]. Nor does either record reviewed address observation without treatment as a comparator ^[1][2]. The landmark standard-of-care trials underpinning either comparator arm were not reviewed in this pass.

Corroboration. Neither trial is confirmed by a company release, a securities filing or a press item in this pass. The verification chain for this story is registry-only, and that is worth stating plainly rather than dressing up.

Who is exposed, by name

The competitive set below is a registry listing of industry-sponsored trials surfaced against the follicular lymphoma landscape query; several are registered in broader B-cell non-Hodgkin lymphoma or CD19-positive populations, as noted per record. It states what each company is testing, never how well anything works, and none of these records is established as registration-directed.

Regeneron carries the deepest registered presence. NCT06097364, active but no longer recruiting, tests odronextamab plus chemotherapy against rituximab plus chemotherapy; NCT06091254, recruiting, tests odronextamab against rituximab combined with different types of chemotherapy ^[9][10]. A Phase 2, NCT03888105, in previously treated B-cell non-Hodgkin lymphoma, is active but no longer recruiting ^[11]. The exposure is positional: Regeneron's Phase 3s are set against chemoimmunotherapy; these two are set against low-intensity therapy in lower-burden and limited-stage populations ^{[1][2][9][10]}. Treatment line is not registered in the records reviewed.

Genmab has epcoritamab in NCT04542824, a Phase 1/2 in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma, and NCT04663347, a Phase 1/2 combination trial built on rituximab-containing backbones — both active but no longer recruiting ^[12][13]. Same rituximab-anchored backbones, one step behind on phase — and neither record reviewed registers rituximab as a randomised comparator ^[12][13].

AstraZeneca appears here separately from surovatamig, with AZD0486 in NCT04594642, a Phase 1 in B-cell non-Hodgkin lymphoma, active but no longer recruiting ^[15]. Nothing in the records reviewed links AZD0486 to surovatamig or to NCT07736950 ^[2][15].

Vironexis Biotherapeutics is the outlier by modality: VNX-101, a gene therapy for CD19-positive haematologic malignancies, in the recruiting Phase 1/2 SENTRY-CD19 study, NCT06533579 ^[14].

What to watch, and when

• 12 January 2027 — the registered start date of NCT07736950. The trial is not yet open, so the first observable event is whether that date holds and whether the status changes to recruiting ^[2].
• 31 March 2032 — the primary completion date of NCT06337318 ^[1].
• 13 January 2035 — the primary completion date of NCT07736950 ^[2].
• Surovatamig's first disclosed dataset — no date attached. The June 2025 headline references EHA 2025; no abstract, presentation or accompanying article text for it is in the sources reviewed, so what was actually presented is unknown ^[4]. No surovatamig presentation is scheduled in anything reviewed; a 4 December 2025 headline surfaced via a news aggregator, describing AstraZeneca's largest-ever presence at ASH and itself unconfirmed in the primary sources reviewed, is the only signal in this pass of the company's haematology congress cadence ^[16].

The now-what

Re-baseline any low tumour burden or limited-stage follicular lymphoma control arm. Both low-intensity comparators are now spoken for by Phase 3 designs, one of them open since 23 October 2024 and currently recruiting toward a 600-patient target ^[1]. Before it is a competition for label language, this is a competition for sites and patients.

Resolve surovatamig's identity before modelling it. Treating it as a confirmed T-cell engager on one trade headline is the exact error to avoid ^[4]. Until an abstract or sponsor disclosure lands, the defensible position is an asset with no target or mechanism in the public record, moving from maximum phase 2 into a randomised Phase 3 in follicular lymphoma ^[3][2].

Decide whether the long horizon is an opening or a moat. Neither reaches its primary completion date before 31 March 2032 ^[1][2], so nothing here forces a competitor's hand this year — but both fix the comparator vocabulary that guideline committees will read in these settings. A shorter, response-based study in the same populations gets to a conversation earlier, and then has to argue against the two designs that got there first.

Verdict: low near-term threat, high structural one. The window to act is the roughly five months before NCT07736950's registered start on 12 January 2027 ^[2].